Monica Arnold
Associate
Monica Arnold is a trial attorney focused on IP litigation. Her work is technologically diverse, including genetically engineered cell therapies and small molecule pharmaceuticals. Previously Monica clerked on the U.S. District Court for the Central District of California and was a litigation associate at Milbank LLP in Los Angeles.
Monica earned her B.S. in Neuroscience from the University of California, Los Angeles, where she investigated the age-dependent impact of oxidative stress on synaptic plasticity in mouse hippocampus in an animal model of neurodegenerative disorders. She then received a Ph.D. in Pharmacology and Toxicology from the University of California, Irvine, where her award-winning research focused on how non-nicotine tobacco components influenced the rewarding aspects of nicotine an animal model of tobacco smoking. At the University of Washington, Monica was a postdoctoral fellow in Psychiatry and Behavioral Sciences where she examined the role of phasic dopamine release in motivation using animal models of reward-based decision-making tasks.
Monica received her J.D. from the University of California, Irvine School of Law, where she received the “Best Outside Legal Counsel” award in the UCI Tech and Entrepreneurship Competition and the Pro Bono 1L achievement award.
Clerkship
U.S. District Court for the Central District of California
Education
J.D., University of California, Irvine
Ph.D., Pharmacology and Toxicology, University of California, Irvine
B.S., Neuroscience, University of California, Los Angeles
Awards
Best Outside Legal Counsel, UCI Tech and Entrepreneurship Competition
Pro Bono 1L achievement award, University of California School of Law
President’s Dissertation Year Fellowship, University of California, Irvine
Fellowship, Society for Neuroscience Scholars Program
Representative Cases
Targus Int’l v. Group III Int’l and Victorinox Swiss Army Inc., Nos. 20-cv-21435 (S.D. Fla.) & 20-464 (D. Del.): successfully represented #1 manufacturer of laptop cases in dispute over checkpoint-friendly travel laptop cases and recovered ~$2M in judgments.
Tris Pharma v. Teva Pharmaceuticals USA, No. 20:20-cv-05212 (D.N.J.): secured important bench trial win for plaintiff on validity and infringement for patents covering Tris’ QuilliChew ER® product, the first long-acting chewable tablet for ADHD. This ruling postpones Teva from commercializing its generic version until at least 2033.
Tris Pharma v. Actavis Laboratories, No. 14-cv-01309 (D. Del.), aff’d No. 21-1495 (Fed. Cir.): secured key bench trial victory for plaintiff on validity and infringement for five patents covering Tris’ Quillivant XR® product, the first liquid long-acting treatment for ADHD. This ruling delays Actavis from commercializing its generic version until at least until 2031.
Media, Speaking Engagements and Publications
Co-author, The Top Five Patent Decisions of 2023, The Recorder (Dec. 2023)
Panelist, Five Things Every Bioengineer Should Know About Patents, California Academy of Bioengineering (Nov. 2023)
Participant, SDIPLA 2023 Mock Markman Competition (Oct. 2023)
Co-author, A Defendant-Friendly Patent Trend In Central District Of California, The Recorder (Aug. 2023)
Co-author, What Happens in Litigation at the Patent Office Doesn’t Stay at the Patent Office, Daily Journal (May 2023)
Teva’s Copy of Tris’ QuilliChew ADHD Drug Blocked Under 2033, Bloomberg Law (Aug. 2022)
Actavis Loss In ADHD Drug IP Fight Backed By Fed. Circ., Law360 (July 2022)
Del. Judge Finds Teva Infringed ADHD Drug IP On Remand, Law360 (Dec. 2020)
Milbank Attys Assist Muslim Nonprofit in Cemetery Fight, Law360 (Nov. 2020)
Co-presenter, Preliminary Injunctions: How to Get Them, How to Avoid Them, World IP Review, (June 2020)
Co-author, Rights Holders Need To Keep Faith In Standard-Essential Patents, IAM Magazine (Aug. 2017)
Co-author, Fast-scan Cyclic Voltammetry In Behaving Animals: Chapter In Basic Electrophysiological Methods, Oxford University Press (Feb. 2015)
Co-author, Dopamine-associated Cached Values Are Not Sufficient As The Basis For Action Selection, PNAS (Dec. 2014)
Co-author, Reinforcing And Neural Activating Effects Of Norharmane, A Non-nicotine Tobacco Constituent, Alone And In Combination With Nicotine, Neuropharmacology (June 2014)
Co-author, Synaptoneurosome Micromethod For Fractionation Of Mouse And Human Brain, And Primary Neuronal Cultures, Journal of Neuroscience Methods (Nov. 2012)
Co-author, The Monoamine Oxidase (MAO) Inhibitor Tranylcypromine Enhances Nicotine Self-Administration In Rats Through A Mechanism Independent Of MAO Inhibition, Neuropharmacology (July 2011)
Co-author, Age-dependent Modulation Of Hippocampal Long-term Potentiation By Antioxidant Enzymes, Journal of Neuroscience Research (Nov. 2006)
Professional Affiliations
Howard T. Markey Intellectual Property Inn of Court, Orange County
ChIPs Network, Orange County Chapter
PTAB Bar Association
Admissions
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Central District of California
U.S. Patent Office
State of California